SERB signs agreement to acquire Idefirix rights for $133.6m

​SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The post SERB signs agreement to acquire Idefirix rights for $133.6m appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.